These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. 1592 (abacavir): do not rechallenge after hypersensitivity reaction. James JS AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916 [TBL] [Abstract][Full Text] [Related]
3. Unusual clinical presentation of hypersensitivity reaction to abacavir. Aquilina C; Mularczyk M; Lucas F; Viraben R AIDS; 2003 Nov; 17(16):2403-4. PubMed ID: 14571198 [No Abstract] [Full Text] [Related]
4. Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients. Bellagamba R; Tommasi C; De Marco M; Narciso P J Infect; 2008 Jul; 57(1):88-90. PubMed ID: 18514915 [No Abstract] [Full Text] [Related]
6. Agranulocytosis and fever seven weeks after starting abacavir. Sankatsing SU; Prins JM AIDS; 2001 Dec; 15(18):2464-5. PubMed ID: 11774836 [No Abstract] [Full Text] [Related]
7. Labeling changes for abacavir. AIDS Patient Care STDS; 2008 Aug; 22(8):683-4. PubMed ID: 18721055 [No Abstract] [Full Text] [Related]
8. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. Waters LJ; Mandalia S; Gazzard B; Nelson M AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891 [TBL] [Abstract][Full Text] [Related]
9. Acute respiratory manifestations of the abacavir hypersensitivity reaction. Herring SJ; Krieger AC AIDS; 2006 Jan; 20(2):301-2. PubMed ID: 16511430 [No Abstract] [Full Text] [Related]
10. Severe hypersensitivity reactions following reintroduction of abacavir. AIDS Read; 2000 Sep; 10(9):525. PubMed ID: 11019447 [No Abstract] [Full Text] [Related]
11. Abacavir warning. AIDS Patient Care STDS; 2000 Nov; 14(11):617. PubMed ID: 11155904 [No Abstract] [Full Text] [Related]
12. Scientists find some genes a bad omen for anti-HIV drug. Stephenson J JAMA; 2002 Apr; 287(13):1637. PubMed ID: 11926874 [No Abstract] [Full Text] [Related]
13. A near-fatal hypersensitivity reaction to abacavir: case report and literature review. Shapiro M; Ward KM; Stern JJ AIDS Read; 2001 Apr; 11(4):222-6. PubMed ID: 11392679 [TBL] [Abstract][Full Text] [Related]
14. Response to: Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients? Brothers C; Cutrell A; Scott T; Hernandez J; Moult A Int J Clin Pract; 2006 May; 60(5):611-2; author reply 612. PubMed ID: 16700867 [No Abstract] [Full Text] [Related]
16. Individualising HIV treatment--pharmacogenetics and immunogenetics. Telenti A; Aubert V; Spertini F Lancet; 2002 Mar; 359(9308):722-3. PubMed ID: 11888578 [No Abstract] [Full Text] [Related]
17. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582 [TBL] [Abstract][Full Text] [Related]
18. Current trends in screening across ethnicities for hypersensitivity to abacavir. Rodriguez-Nóvoa S; Soriano V Pharmacogenomics; 2008 Oct; 9(10):1531-41. PubMed ID: 18855539 [TBL] [Abstract][Full Text] [Related]
19. 'Fine tuning' HIV therapy. Report on the 9th Conference on Retroviruses and Opportunistic Infections. Linde M Posit Living; 2002; 11(3):8-9, 16, 44. PubMed ID: 12035759 [No Abstract] [Full Text] [Related]
20. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity. Frissen PH; de Vries J; Weigel HM; Brinkman K AIDS; 2001 Jan; 15(2):289. PubMed ID: 11216946 [No Abstract] [Full Text] [Related] [Next] [New Search]